

Regulatory Acceptance and Implementation of 3R Approaches

Activities of The European Partnership for Alternative Approaches to Animal Testing (EPAA)

Julia Scheel (Henkel)

i-SUP Meeting 2008 April 22-25, Brugge, Belgium

Introduction

SR approaches can only be successfully implemented if the results are accepted by regulatory authorities worldwide

Therefore, EPAA is dedicated to identify and overcome hurdles of the acceptance of methods and their regulatory implementation




EPAA: Partnership for Alternative Approaches to Animal Testing


- Launch in November 2005
- Partners:
 - A joint initiative between the Commission services, more than 35 individual companies and 7 trade federations
- Objective:
 - To promote research, development, validation, dissemination, regulatory acceptance and implementation of 3Rs, based on the "Brussels 3Rs declaration"

• Scope:

- Regulatory testing in currently seven industry fields (chemicals, human and veterinary medicines, cosmetics, hygiene products, crop protection, biotechnology)
- More information: **www.epaa.eu.com**



<u>The EPAA Action Programme:</u> <u>5 Interlinking Themes Dealt by 5 Working Groups</u>



Regulatory Acceptance and Implementation of 3R <u>Approaches</u>

- Analysis of regulatory requirements and major drivers behind regulatory testing: potential hot spots and issues for further discussion in various sectors
- Identification of potential hurdles for uptake of 3Rs techniques, e.g. precautionary principle, liability issues
- Statistical reporting of animals in regulatory testing: May it facilitate and confirm the implementation of the 3Rs?



- Identifying and promoting opportunities to facilitate and accelerate the validation and acceptance procedures
- Understanding sector-specific acceptance criteria
- Analysing case studies to identify barriers and delays to validation and regulatory acceptance
- Enhanced collaboration between industry and ECVAM to prioritise and facilitate the validation of alternative methods/strategies



Different Sectors and a Plethora of Regulations

Chemicals: 67/548/EEC, REACH, GHS ...

Human and Veterinary Pharmaceuticals: 2001/83/EC, 2001/20/EC, ICH Guidelines...

Animal protection: Directive 86/609/EC

Cosmetics: 76/768/EEC, 7th amendment ...

Food&Feed:

EC/178/2002,

89/107/EEC ...

Agrochemicals/ Crop Protection: 91/414/EEC...

Product liability: 85/374/EC...

Activities in 2007 Involving Relevant Stakeholders

Workshop on Regulatory Acceptance http://ec.europa.eu/enterprise/epaa/wg_5_1.htm

Meeting on Statistical Reporting

http://ec.europa.eu/enterprise/epaa/wg4_statistical_reporting_3rs.pdf

EPAA Annual Conference: Regulatory Acceptance as Main Theme

http://ec.europa.eu/enterprise/epaa/conf_2007.htm

Major Outcomes were Related to

- I. Analysis of sector-specific requirements: regulation, acceptance criteria
- II. Linking validation and acceptance
- III. Usefulness of current statistical reporting
- IV. Relation between legal issues and scientific criteria
- V. International dialogue



I. Sector-specific Requirements

Requirements differ depending on the respective legal framework

- Mandatory (regulation) and flexible elements (guidelines/guidance) may exist
- Some sectors benefit already from an international process like ICH, as well as from an integration of regulators, industry and academics



II. Linking Validation to Acceptance and Implementation


In order to enable efficient uptake and acceptance of 3R methods, validation and acceptance should go hand in hand

> Scientifc robustness is a main driver for acceptance

Regulators, and also other potential users of a method should be involved already in early stages of the process: dissemination, training, feedback




Suggested Expanded Modular Approach to Validation: element of building trust in a method



Securing regulatory relevance and acceptance to trigger more support from all stakeholders : ECVAM's proposal for ERAP (European Regulatory Advisory Panel)

III. Statistical Reporting of Animals:

Suitability of Current Statistics



- Statistics are not the appropriate tool to measure the success of alternative approaches in general
- Only limited aspects of the 3Rs might be detected: changes in the use of specific methods, changes in testing per product type, switch from "higher" to "lower" species, severity where it is reported
- Revision of Directive 86/609/EEC ongoing including the requirements for statistical reporting
- EPAA to identify other ways of assessing the uptake of 3R approaches

IV. Legal Issues and Scientific Criteria

- "Duty of Care"- safety needs to be ensured in the first place (precautionary principle referred to e.g. in REACH)
- "Burden of Proof"- sufficient data and justification is required: Methods need to be scientifically acceptable / accepted
- > Which data is acceptable or is the best data?
- Liability is linked to the state of scientific and technical knowledge

State of Scientific and Technical Knowledge -Toxicology Paradigms at Stake

Following the current paradigm, animal tests in many cases are seen as the "gold standard", but might also lack validation

There is less experience with data from alternative methods in risk assessment

Regulators and safety assessors might not accept a method as such, but as a precaution only acknowledge positive results



V. International Dialogue

Cross-sectoral exchange useful (data, experience)

- Global dimension: Regional implementation of 3R methods usually impossible - authorities from different countries often require different data
- More transparency and efficient communication between regulators, industry and "xCVAMs" required
- Interlinked processes and efficient mechanisms needed
- An international regulatory dialogue is essential for global acceptance

Conclusions

Industry and regulators have a common challenge: Securing best safety for human health and at the same time applying alternative approaches wherever possible

EPAA's role is to provide a platform for communication and information exchange in order to accelerate acceptance and implementation, with a specific emphasis on cross-sectoral links.

→ Further actions will be identified and reviewed with appropriate key players



<u>Outlook</u>

- Follow-up on WS on regulatory acceptance and Annual Conference outcomes: Addressing barriers to acceptance
- EPAA workshop at ECVAM addressing barriers to validation
- Setting up new "horizontal", cross-sectoral case studies, e.g. on acute toxicity testing requirements throughout sectors
- Monitoring implementation of existing and new regulation: scope for optimisation of 3Rs uptake (e.g. REACH)

Thank you for your attention!

